952 related articles for article (PubMed ID: 12420225)
21. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
22. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
Du J; Jiang B; Coffey RJ; Barnard J
Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
[TBL] [Abstract][Full Text] [Related]
23. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
Bernhard EJ; Kao G; Cox AD; Sebti SM; Hamilton AD; Muschel RJ; McKenna WG
Cancer Res; 1996 Apr; 56(8):1727-30. PubMed ID: 8620483
[TBL] [Abstract][Full Text] [Related]
24. TGF-beta1 (transforming growth factor-beta1)-mediated adhesion of gastric carcinoma cells involves a decrease in Ras/ERKs (extracellular-signal-regulated kinases) cascade activity dependent on c-Src activity.
Kim HP; Lee MS; Yu J; Park JA; Jong HS; Kim TY; Lee JW; Bang YJ
Biochem J; 2004 Apr; 379(Pt 1):141-50. PubMed ID: 14720123
[TBL] [Abstract][Full Text] [Related]
25. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
26. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes.
Bernhard EJ; McKenna WG; Hamilton AD; Sebti SM; Qian Y; Wu JM; Muschel RJ
Cancer Res; 1998 Apr; 58(8):1754-61. PubMed ID: 9563495
[TBL] [Abstract][Full Text] [Related]
27. Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.
Elbendary A; Berchuck A; Davis P; Havrilesky L; Bast RC; Iglehart JD; Marks JR
Cell Growth Differ; 1994 Dec; 5(12):1301-7. PubMed ID: 7696178
[TBL] [Abstract][Full Text] [Related]
28. Regulation of transforming growth factor beta receptors in H-ras oncogene-transformed rat intestinal epithelial cells.
Zhao J; Buick RN
Cancer Res; 1995 Dec; 55(24):6181-8. PubMed ID: 8521411
[TBL] [Abstract][Full Text] [Related]
29. Requirement of TGF-beta receptor-dependent activation of c-Jun N-terminal kinases (JNKs)/stress-activated protein kinases (Sapks) for TGF-beta up-regulation of the urokinase-type plasminogen activator receptor.
Yue J; Sun B; Liu G; Mulder KM
J Cell Physiol; 2004 May; 199(2):284-92. PubMed ID: 15040011
[TBL] [Abstract][Full Text] [Related]
30. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS.
Cohen-Jonathan E; Toulas C; Ader I; Monteil S; Allal C; Bonnet J; Hamilton AD; Sebti SM; Daly-Schveitzer N; Favre G
Radiat Res; 1999 Oct; 152(4):404-11. PubMed ID: 10477917
[TBL] [Abstract][Full Text] [Related]
31. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
[TBL] [Abstract][Full Text] [Related]
32. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
Rak J; Mitsuhashi Y; Bayko L; Filmus J; Shirasawa S; Sasazuki T; Kerbel RS
Cancer Res; 1995 Oct; 55(20):4575-80. PubMed ID: 7553632
[TBL] [Abstract][Full Text] [Related]
33. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
34. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
[TBL] [Abstract][Full Text] [Related]
35. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
Du W; Lebowitz PF; Prendergast GC
Cancer Res; 1999 May; 59(9):2059-63. PubMed ID: 10232587
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma.
Kim J; Seong J; Kim SH
Ann N Y Acad Sci; 2004 Dec; 1030():95-102. PubMed ID: 15659785
[TBL] [Abstract][Full Text] [Related]
37. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
Wittrock J; Schweizer P; Girgert R
Anticancer Res; 2002; 22(6C):4205-9. PubMed ID: 12553057
[TBL] [Abstract][Full Text] [Related]
38. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
39. Restored expression of transforming growth factor beta type II receptor in k-ras-transformed thyroid cells, TGF beta-resistant, reverts their malignant phenotype.
Coppa A; Mincione G; Lazzereschi D; Ranieri A; Turco A; Lucignano B; Scarpa S; Ragano-Caracciolo M; Colletta G
J Cell Physiol; 1997 Aug; 172(2):200-8. PubMed ID: 9258341
[TBL] [Abstract][Full Text] [Related]
40. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
